^
Association details:
| Biomarker: | MET exon 14 mutation + MET amplification + PD-L1 overexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tepmetko (tepotinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP08.02-056 - Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors
Published date:
07/12/2022
Excerpt:
This 64-year-old male patient...whose path report showed lung adenocarcinoma. FoundationOne CDx panel demonstrated MET exon 14 skipping mutation (3038+3A>G, allelic fraction > 80%) plus MET amplification (12 copy numbers). PD-L1 expression (22C3) was 90%....Two months after tepotinib was started, complete radiologic response was achieved, and patient continues on treatment without evidence of disease after 1 year.
